United States-based MCI Diagnostic Center, a Service-Disabled Veteran-Owned small business that provides national laboratory testing and diagnostics in all 50 states, has launched a new laboratory in Dallas, Texas, it was reported on Friday.
The company is an SBA HUBZone certified and accredited by CLIA, CAP, COLA and FDA.
At the laboratory's official opening, Colleen Payne-Nabors MCI Diagnostic Center COO, said, 'We are providing a wonderful service in this time of need for our country. I thank each of you for coming and supporting the grand opening of MCI and we look forward to a long and healthy relationship on the other side of COVID-19.'
AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer
Transcend Therapeutics acquired by Otsuka Pharmaceutical
Rocket Pharmaceuticals closes USD180m Rare Pediatric Disease voucher sale
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer
Formosa Pharmaceuticals signs Vietnam licensing deal with Samil Pharmaceuticals
Harbour BioMed IND for HBM7004 accepted by China's NMPA
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector